Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Leerink Partnrs boosted their Q4 2024 earnings per share (EPS) estimates for Viking Therapeutics in a report released on Wednesday, April 24th. Leerink Partnrs analyst T. Smith now anticipates that the biotechnology company will earn ($0.25) per share for the quarter, up from their previous forecast of ($0.26). The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.05) per share. Leerink Partnrs also issued estimates for Viking Therapeutics' FY2025 earnings at ($1.64) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($3.46) EPS and FY2028 earnings at ($1.19) EPS.
A number of other research analysts also recently issued reports on VKTX. Truist Financial increased their price objective on Viking Therapeutics from $32.00 to $120.00 and gave the stock a "buy" rating in a report on Thursday, February 29th. Stifel Nicolaus reiterated a "buy" rating and set a $80.00 price objective on shares of Viking Therapeutics in a report on Friday, March 15th. StockNews.com upgraded Viking Therapeutics to a "sell" rating in a report on Thursday. Oppenheimer increased their price target on Viking Therapeutics from $116.00 to $138.00 and gave the company an "outperform" rating in a research report on Tuesday, March 26th. Finally, BTIG Research increased their price target on Viking Therapeutics from $100.00 to $125.00 and gave the company a "buy" rating in a research report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $112.25.
Get Our Latest Stock Report on VKTX
Viking Therapeutics Stock Up 1.5 %
Shares of NASDAQ:VKTX traded up $1.11 during mid-day trading on Monday, reaching $75.42. 2,827,228 shares of the stock were exchanged, compared to its average volume of 5,566,897. The company has a market cap of $8.31 billion, a P/E ratio of -80.37 and a beta of 1.05. Viking Therapeutics has a one year low of $8.28 and a one year high of $99.41. The stock's 50 day simple moving average is $69.11 and its 200-day simple moving average is $35.56.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.01. During the same period in the prior year, the company earned ($0.25) earnings per share.
Insider Buying and Selling
In other news, Director Sarah Kathryn Rouan sold 25,000 shares of the stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $28.05, for a total transaction of $701,250.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, Director Sarah Kathryn Rouan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $28.05, for a total transaction of $701,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Brian Lian sold 35,000 shares of the firm's stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $23.95, for a total transaction of $838,250.00. Following the sale, the chief executive officer now owns 2,264,882 shares of the company's stock, valued at approximately $54,243,923.90. The disclosure for this sale can be found here. Insiders have sold a total of 329,079 shares of company stock valued at $8,769,653 over the last 90 days. 4.70% of the stock is owned by insiders.
Institutional Investors Weigh In On Viking Therapeutics
Several large investors have recently modified their holdings of the stock. Caas Capital Management LP bought a new position in Viking Therapeutics in the 1st quarter worth approximately $2,706,000. K.J. Harrison & Partners Inc bought a new stake in shares of Viking Therapeutics during the 1st quarter valued at about $328,000. LifeSteps Financial Inc. bought a new stake in shares of Viking Therapeutics during the 1st quarter valued at about $37,000. Lindbrook Capital LLC boosted its stake in shares of Viking Therapeutics by 370.7% during the 1st quarter. Lindbrook Capital LLC now owns 353 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 278 shares in the last quarter. Finally, Gainplan LLC bought a new stake in Viking Therapeutics during the first quarter worth about $246,000. Hedge funds and other institutional investors own 76.03% of the company's stock.
About Viking Therapeutics
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Further Reading
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
